BlackRock Inc. boosted its stake in OptimizeRx Co. (NASDAQ:OPRX) by 2,111.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 607,292 shares of the company’s stock after acquiring an additional 579,833 shares during the period. BlackRock Inc. owned about 4.30% of OptimizeRx worth $9,839,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in OPRX. Strs Ohio acquired a new position in OptimizeRx in the second quarter valued at $51,000. Atlantic Trust LLC acquired a new position in OptimizeRx in the second quarter valued at $126,000. Wells Fargo & Company MN increased its stake in OptimizeRx by 9.5% in the second quarter. Wells Fargo & Company MN now owns 13,562 shares of the company’s stock valued at $219,000 after purchasing an additional 1,180 shares during the period. Charles Schwab Investment Management Inc. acquired a new position in OptimizeRx in the second quarter valued at $454,000. Finally, Bank of New York Mellon Corp acquired a new position in OptimizeRx in the second quarter valued at $488,000. 56.07% of the stock is owned by hedge funds and other institutional investors.
NASDAQ OPRX opened at $13.62 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.80 and a current ratio of 6.80. The firm has a market cap of $199.35 million, a PE ratio of 272.40, a P/E/G ratio of 1.60 and a beta of 0.39. OptimizeRx Co. has a one year low of $8.92 and a one year high of $18.00. The firm’s fifty day moving average is $14.94 and its two-hundred day moving average is $14.40.
OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.03 EPS for the quarter, meeting analysts’ consensus estimates of $0.03. The company had revenue of $7.01 million for the quarter, compared to analyst estimates of $6.78 million. OptimizeRx had a net margin of 2.27% and a return on equity of 2.89%. Research analysts predict that OptimizeRx Co. will post 0.22 earnings per share for the current year.
OPRX has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of OptimizeRx from a “buy” rating to a “hold” rating in a research note on Wednesday, October 9th. ValuEngine lowered shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 7th.
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
Further Reading: Understanding Market Liquidity
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.